{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:20:58Z","timestamp":1782224458891,"version":"3.54.5"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Diagnostic Pathology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semdp.2025.150915","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T15:01:53Z","timestamp":1747494113000},"page":"150915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cytogenetic and molecular aberrations at diagnosis and in prognosis of multiple myeloma"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5140-3633","authenticated-orcid":false,"given":"Beenu","family":"Thakral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjanaa","family":"Vijayanarayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semdp.2025.150915_bib0001","unstructured":"National cancer institute. cancer stat facts: myeloma. [Internet]. 2024. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"issue":"12","key":"10.1016\/j.semdp.2025.150915_bib0002","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.semdp.2025.150915_bib0003","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.semdp.2025.150915_bib0004","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semdp.2025.150915_bib0005","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5858\/arpa.2012-0209-OA","article-title":"Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms","volume":"137","author":"Lu","year":"2013","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.semdp.2025.150915_bib0006","doi-asserted-by":"crossref","first-page":"87","DOI":"10.14740\/jh1007","article-title":"Conventional karyotyping and fluorescence In situ hybridization for detection of chromosomal abnormalities in multiple myeloma","volume":"11","author":"Crabtree","year":"2022","journal-title":"J Hematol"},{"issue":"11","key":"10.1016\/j.semdp.2025.150915_bib0007","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/sj.leu.2403518","article-title":"Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma","volume":"18","author":"Kaufmann","year":"2004","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.semdp.2025.150915_bib0008","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response","volume":"10","author":"Abdallah","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.semdp.2025.150915_bib0009","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.semdp.2025.150915_bib0010","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.semdp.2025.150915_bib0011","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-024-01075-x","article-title":"Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells","volume":"14","author":"D'Agostino","year":"2024","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.semdp.2025.150915_bib0012","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3324\/haematol.2017.168005","article-title":"Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation","volume":"102","author":"Merz","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.semdp.2025.150915_bib0013","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1159\/000521902","article-title":"The prognostic impact of MYC gene-related abnormalities on multiple myeloma outcome through fluorescence in situ hybridization analysis","volume":"145","author":"Okada","year":"2022","journal-title":"Acta Haematol"},{"issue":"24","key":"10.1016\/j.semdp.2025.150915_bib0014","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-20-2283","article-title":"Implications of MYC rearrangements in newly diagnosed multiple myeloma","volume":"26","author":"Abdallah","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.semdp.2025.150915_bib0015","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1073\/pnas.1514586113","article-title":"Nuclear TRAF3 is a negative regulator of CREB in B cells","volume":"113","author":"Mambetsariev","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"10.1016\/j.semdp.2025.150915_bib0016","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"10.1016\/j.semdp.2025.150915_bib0017","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.semdp.2025.150915_bib0018","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1158\/1078-0432.CCR-12-3866","article-title":"The translocation t(4;14) can be present only in minor subclones in multiple myeloma","volume":"19","author":"Hebraud","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semdp.2025.150915_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1243997","article-title":"Molecular and immunological mechanisms of clonal evolution in multiple myeloma","volume":"14","author":"Forster","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.semdp.2025.150915_bib0020","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fernandez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.semdp.2025.150915_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020209","article-title":"The cytogenetic profile of primary and secondary plasma cell leukemia: etiopathogenetic perspectives, prognostic impact and clinical relevance to newly diagnosed multiple myeloma with differential circulating clonal plasma cells","volume":"10","author":"Papadhimitriou","year":"2022","journal-title":"Biomedicines"},{"issue":"14","key":"10.1016\/j.semdp.2025.150915_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411259","article-title":"Genetic abnormalities in extramedullary multiple myeloma","volume":"24","author":"McAvera","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.semdp.2025.150915_bib0023","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.semdp.2025.150915_bib0024","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-023-00919-2","article-title":"Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma","volume":"13","author":"Liu","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.semdp.2025.150915_bib0025","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semdp.2025.150915_bib0026","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.semdp.2025.150915_bib0027","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1038\/s41467-021-25469-8","article-title":"Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma","volume":"12","author":"Maclachlan","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.semdp.2025.150915_bib0028","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.semdp.2025.150915_bib0029","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1182\/blood-2010-12-328252","article-title":"Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3","volume":"118","author":"Shaughnessy","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semdp.2025.150915_bib0030","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/leu.2012.127","article-title":"A gene expression signature for high-risk multiple myeloma","volume":"26","author":"Kuiper","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.semdp.2025.150915_bib0031","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jha2.209","article-title":"Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial","volume":"2","author":"Biran","year":"2021","journal-title":"EJHaem"},{"issue":"2","key":"10.1016\/j.semdp.2025.150915_bib0032","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/ejh.13541","article-title":"Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA","volume":"106","author":"Deshpande","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.semdp.2025.150915_bib0033","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2021-146535","article-title":"Circulating tumor cells (CTCs) in smoldering and active multiple myeloma (MM): mechanism of egression, clinical significance and therapeutic endpoints","volume":"138","author":"Garc\u00e9s","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semdp.2025.150915_bib0034","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41568-024-00755-x","article-title":"Ghobrial IM. New horizons in our understanding of precursor multiple myeloma and early interception","volume":"24","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.semdp.2025.150915_bib0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"26","key":"10.1016\/j.semdp.2025.150915_bib0036","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semdp.2025.150915_bib0037","first-page":"5991","article-title":"Concepts of double hit and triple hit disease in multiple myeloma","volume":"10","author":"Baysal","year":"2020","journal-title":"Entity and Prognostic Significance. Sci Rep."},{"issue":"3","key":"10.1016\/j.semdp.2025.150915_bib0038","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41576-019-0180-9","article-title":"Structural variation in the sequencing era","volume":"21","author":"Ho","year":"2020","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.semdp.2025.150915_bib0039","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.semdp.2025.150915_bib0040","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/s41375-018-0103-3","article-title":"Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms","volume":"32","author":"Hoang","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.semdp.2025.150915_bib0041","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.semdp.2025.150915_bib0042","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.semdp.2025.150915_bib0043","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semdp.2025.150915_bib0044","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-018-0160-x","article-title":"Molecular signatures of multiple myeloma progression through single cell RNA-seq","volume":"9","author":"Jang","year":"2019","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.semdp.2025.150915_bib0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","article-title":"Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine","volume":"19","author":"Dutta","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.semdp.2025.150915_bib0046","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.semdp.2025.150915_bib0047","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.semdp.2025.150915_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.semdp.2025.150915_bib0049","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/blood.V126.23.191.191","article-title":"Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM\/DFCI 2009 trial","volume":"126","author":"CJ","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semdp.2025.150915_bib0050","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.165217","article-title":"The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype","volume":"102","author":"Schinke","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.semdp.2025.150915_bib0051","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.27327","article-title":"High-risk multiple myeloma: redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy","volume":"99","author":"Rees","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.semdp.2025.150915_bib0052","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433520","article-title":"Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies","volume":"44","author":"Rees","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.semdp.2025.150915_bib0053","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/10428194.2024.2443550","article-title":"Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future","volume":"66","author":"Zanwar","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.semdp.2025.150915_bib0054","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.semdp.2025.150915_bib0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.semdp.2025.150915_bib0056","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1182\/blood-2023-182845","article-title":"Deletion 1p at time of diagnosis of multiple myeloma portends inferior outcomes","volume":"142","author":"Vaishnav","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semdp.2025.150915_bib0057","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/leu.2013.225","article-title":"Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients","volume":"28","author":"Hebraud","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.semdp.2025.150915_bib0058","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.V95.6.1925","article-title":"Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization","volume":"95","author":"Zojer","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semdp.2025.150915_bib0059","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1038\/bcj.2017.83","article-title":"Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma","volume":"7","author":"Binder","year":"2017","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1016\/j.semdp.2025.150915_bib0060","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1158\/1078-0432.CCR-21-0005","article-title":"The prognostic role of MYC structural variants identified by NGS and FISH in multiple myeloma","volume":"27","author":"Sharma","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.semdp.2025.150915_bib0061","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semdp.2025.150915_bib0062","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ijlh.12882","article-title":"Recent advances in cytogenetic characterization of multiple myeloma","volume":"41","author":"Saxe","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"10.1016\/j.semdp.2025.150915_bib0063","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-019-02725-3","article-title":"A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration","volume":"476","author":"Schurch","year":"2020","journal-title":"Virchows Arch"}],"container-title":["Seminars in Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257025000516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257025000516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T02:04:47Z","timestamp":1749261887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740257025000516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0740257025000516"],"URL":"https:\/\/doi.org\/10.1016\/j.semdp.2025.150915","relation":{},"ISSN":["0740-2570"],"issn-type":[{"value":"0740-2570","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytogenetic and molecular aberrations at diagnosis and in prognosis of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semdp.2025.150915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"150915"}}